ReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation

ReproNovo, a clinical-stage biopharmaceutical company committed to addressing critical gaps in male and female fertility as well as women’s health, today announced that the first participant has been dosed in…

Continue ReadingReproNovo announces first participant dosed in EU Phase 2 trial of RPN-002 for embryo implantation